EUVIMEDEUVIMED entdecken
Open Access

Combination therapy blocking TNF superfamily members 14 and 15 reverses pulmonary fibrosis

Hope Steele iD, Ashley Willicut iD, Garrison Dell, Andrew Ghastine iD, Xinh-Xinh Nguyen, Paul Lembicz, Hailey Doerflein, Therese Suchoski, Elizabeth Kato, Carol Feghali-Bostwick, Michael Croft, Rana Herro iD

The Journal of Immunology · 2025

DOI: 10.1093/jimmun/vkaf002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, 2025. Verfasst von Hope Steele und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States. Hauptthemen laut MEDLINE: Tumor Necrosis Factor Ligand Superfamily Member 15, Pulmonary Fibrosis, Tumor Necrosis Factor Ligand Superfamily Member 14. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, Cincinnati Children's Hospital Medical Center, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Currently, anti-inflammatory drugs fail to reduce pulmonary fibrosis and tissue remodeling in the clinic. Thus, there is an unmet need to develop novel antifibrotic drugs capable of reversing disease. Our lab has identified two novel mediators of pulmonary fibrosis belonging to the tumor necrosis factor superfamily (TNFSF), LIGHT (TNFSF14) and TL1A (TNFSF15). Aside from their inflammatory roles, LIGHT and TL1A can directly activate structural cells involved in fibrosis, which express their receptors. Here, we show that LIGHT and TL1A receptors are both significantly elevated in patient pulmonary fibrosis biopsies as compared with healthy control lungs. Using gain-of-function studies, we found that LIGHT and TL1A can drive airway remodeling independently of one another. Furthermore, these TNFSF members synergize to maximize airway inflammation and fibrosis. We show that the combinatorial blockade of LIGHT and TL1A limits transforming growth factor β–driven profibrotic effects on fibroblasts in vitro. Moreover, LIGHT and TL1A stimulation of human epithelial cells and fibroblasts reveal distinct fibrotic signatures, including additive and synergistic profibrotic activities, in addition to some redundant profibrotic functions. Importantly, using antagonistic reagents neutralizing both LIGHT and TL1A signaling concomitantly post–disease onset in a bleomycin mouse model of pulmonary fibrosis, we observe a significant decrease in collagen deposition and smooth muscle accumulation as opposed to respective monotherapies blocking each molecule in isolation. This work highlights a therapeutic need to concomitantly target LIGHT and TL1A for treatment of pulmonary fibrosis disorders in humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Necrosis Factor Ligand Superfamily Member 15Pulmonary FibrosisTumor Necrosis Factor Ligand Superfamily Member 14HumansAnimalsMiceBleomycinFibroblastsMice, Inbred C57BLAirway RemodelingLungDrug Therapy, CombinationDisease Models, Animal

Stichwörter der Autor:innen

TNFSFfibrosisinflammationlungstromal cells

Substanzen

Tumor Necrosis Factor Ligand Superfamily Member 15Tumor Necrosis Factor Ligand Superfamily Member 14TNFSF15 protein, humanBleomycinTNFSF14 protein, human

Autor:innen und Institutionen

  • Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
  • Immunology Graduate Program, University of Cincinnati, Cincinnati, OH, United States.
  • University of Cincinnati College of Medicine, Cincinnati, OH, United States.
  • Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, United States.
  • Division of Immune Regulation, La Jolla Institute for Immunology, La Jolla, CA, United States.
  • Department of Pediatrics, University of Cincinnati, Cincinnati, OH, United States.

ORCID-Profile: Hope Steele, Ashley Willicut, Andrew Ghastine, Rana Herro

Förderung

  • NIAID NIH HHS
  • Cincinnati Children's Hospital Medical Center
  • NIH HHS
  • National Institutes of Health
  • Cincinnati Children’s Hospital Medical Center

Zitieren

APA

Steele, H., Willicut, A., Dell, G., Ghastine, A., Nguyen, X. X., Lembicz, P., Doerflein, H., Suchoski, T., Kato, E., Feghali-Bostwick, C., Croft, M., & Herro, R. (2025). Combination therapy blocking TNF superfamily members 14 and 15 reverses pulmonary fibrosis. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf002

Vancouver

Steele H, Willicut A, Dell G, Ghastine A, Nguyen XX, Lembicz P, et al. Combination therapy blocking TNF superfamily members 14 and 15 reverses pulmonary fibrosis. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkaf002

BibTeX
@article{Steele2025,
  author = {Steele, Hope and Willicut, Ashley and Dell, Garrison and Ghastine, Andrew and Nguyen, Xinh-Xinh and Lembicz, Paul and Doerflein, Hailey and Suchoski, Therese and Kato, Elizabeth and Feghali-Bostwick, Carol and Croft, Michael and Herro, Rana},
  title = {Combination therapy blocking TNF superfamily members 14 and 15 reverses pulmonary fibrosis},
  journal = {The Journal of Immunology},
  year = {2025},
  doi = {10.1093/jimmun/vkaf002}
}
Kostenlos starten →